Suggestions




·

Mecure Industries Is Worst-Performing Pharmaceutical Stock Year-To-Date

May 13, 2025
by

Mecure Industries is the worst-performing pharmaceutical stock so far in 2025, according to Prime Business Africa’s analysis of its stock market activity in the last five months.

The analysis showed that the company’s share price fell by N2.8 kobo from N13.90 kobo on January 2 to N11.10 kobo on May 9, indicating that investors don’t consider Mecure’s share as a valuable asset to hold.

Join our WhatsApp Channel

The 20.14 per cent decline in share price denotes that stock market investors were bearish on Mecure’s shares, which implies that they believe the asset will experience a downward trajectory.

The expectation cost Mecure’s shareholders a combined loss of N11.2 billion between January and May, representing a 20.14 per cent decline in their investment.

In addition, Mecure’s market valuation dropped from N55.6 billion recorded at the start of the first quarter, to N44.4 billion as of May 9, according to analysis.

The company’s struggle to attract investors comes amid its report that Q1 2025 cost of sales grew faster than revenue, surpassing the turnover generated in the first quarter of last year, and its finance cost dragged down net income.

Checks by Prime Business Africa showed that Mecure had recorded 64.53 percent in its revenue, after generating N13.29 billion in Q1 2025, surpassing the N8.07 billion turnover reported in Q1 2024.

However, the cost of sales grew by 66.23 percent year-on-year, from N5.41 billion to N8.99 billion, leaving Mecure with N4.29 billion gross profit, which is 61.08 percent higher than the N2.66 billion filed in Q1 last year.

After accounting for marketing expenses, administrative expenses and other income, Mecure recorded an operating profit of N2.56 billion, up by 54.98 percent year-on-year from N1.65 billion.

But a 137.16 per cent year-on-year increase in finance cost, which comprises interest expense on borrowings, and rose from N739.56 million to N1.75 billion, negatively impacted Mecure’s bottom line, as profit before tax fell by 11.34 per cent.

According to the company’s financials, profit before tax fell to N812.43 million in the first quarter of 2025, from N916.4 million reported in the corresponding period last year.

After deducting income tax, Mecure had N568.70 million as profit after tax (PAT) in Q1 this year, falling to exceed the N641.48 million reached in Q1 the year before.

For press releases, tip-offs, and corporate information, call 08149575257 (hotline)
Email: publisher@primebusiness.africa and editor@primebusiness.africa

+ posts

Prime Business Africa

Related Posts

Previous Story

Northern Governors’ Shift On State Police Raises Questions

Next Story

Super Eagles Striker, Awoniyi, Undergoes ‘Urgent’ Surgery

Featured Stories

Related Posts

Latest from Business

Black Market, Official Window FX Rates Gap Widens By N100

The gap between the black market and the official window widened to N100.88 kobo on Monday, February 16, from N49.58 kobo on Friday, February 13. In the black market on Monday, the foreign exchange (FX) rate for the United States dollar (USD) increased

BUA Group Signs Strategic Partnership with UAE Firms

BUA Group has signed a strategic Memorandum of Understanding (MoU) with UAE-based AD Ports Group and MAIR Group in Abu Dhabi, in a deal aimed at strengthening industrial development, trade, and logistics between West Africa, the Gulf, and Asia. The agreement follows
Previous Story

Northern Governors’ Shift On State Police Raises Questions

Next Story

Super Eagles Striker, Awoniyi, Undergoes ‘Urgent’ Surgery

Don't Miss

U.S. Sanctions On Nigeria Over Religious Killings: Implications On Bilateral Relations

The proposed imposition of sanctions on Nigeria by the United
Stock Exchange

Losses In Ecobank, RT Briscoe Sink Stock Market By N313.01 billion

Nigerian bourse depreciated by -1.03 per cent, costing stock investors